

CURRICULUM VITAE

Rahul K. Reddy, MD
rreddy375@yahoo.com
(419) 509-5009

Education:

The Vanderbilt Eye Institute, Nashville, TN <i>Fellowship in Vitreoretinal diseases and surgery</i>	Jul 2009 – Jun 2011
Dept. of Ophthalmology and Visual Sciences, Cleveland, OH University Hospitals/Case Medical Center <i>Ophthalmology Resident</i>	Jul 2006 – Jun 2009
Summa Health Systems/NEOUCOM, Akron, OH <i>Transitional year resident - Internship</i>	Jul 2004 – Jul 2005
Bascom Palmer Eye Institute, Miami, FL <i>Ocular Pathology Fellowship, 2004</i>	Jul 2003 – Jul 2004
Medical College of Ohio at Toledo, Toledo, OH <i>Doctor of Medicine, 2003</i>	Aug 1999 – Jun 2003
Johns Hopkins School of Public Health, Baltimore, MD <i>Masters in Health Science, 1998</i>	Jun 1997 – Jun 1998
University of Cincinnati, Cincinnati, OH <i>Bachelor in Science, 1996 Cum laude</i>	Sep 1994 – May 1996

Honors/Awards:

- Selected as "Phoenix Top Doc" 2018
- Selected as one of "Americas Top Doctors" by Castle and Connolly 2018
- Selected in "Leading Physicians of the World" 2016
- J. Donald M. Gass Fellowship Award, The Vanderbilt Eye Institute (2010)
- Best "Research Day" project award, University Hospitals/Case Medical Center (2009)
- Highest quiz score award, University Hospitals/Case Medical Center (2008)
- Best "Research Day" project award, University Hospitals/Case Medical Center (2006)
- IRTA Fellowship Award from the National Cancer Institute (1996)
- President of the Medical Student Council (1999-2002)

Major Field: Vitreoretinal Surgery/Ophthalmology

Employment:

8/2011 - Present Associated Retina Consultants, Ltd. Phoenix, AZ
Assistant Clinical Professor - University of Arizona Medical School
Fellowship Director: Associated Retinal Consultants of Phoenix
Director of Clinical Research Division: Associated Retinal Consultants of Phoenix

Board Certifications:

Board Certified by American Board of Ophthalmology since 2012

Medical License:

AZ:	45001	Issued: 05/09/2011	Exp. 03/25/2015
TN:	MD000044814	Issued: 04/08/2009	Exp. 03/31/2011
OH:	35.087066	Issued: 10/14/2005	Exp. 04/01/2012
AZ DEA:	FR2585024	Issued: 05/18/2011	Exp. 04/30/2014

Service:

- American Society of Retinal Specialists
- American Academy of Ophthalmology
- The Association for Research in Vision and Ophthalmology
- Eyetext.net Global Ophthalmic Community member
- Editorial/Reviewer: JSM Ophthalmology
- Editorial/Reviewer: Eye and Vision
- Editorial/Review Board Member JSM Nutritional Disorders
- Editorial/Reviewer: Case Reports in Ophthalmology
- Editorial/Reviewer: International Journal of Ophthalmology and Clinical Research

Abstract / Presentations:

- **Femtosecond Laser Assisted Cataract Surgery in a Case of Traumatic Cataract Following Penetrating Ocular Injury.** Brems, R, Reddy R. American Society of Refractive and Cataract Surgery. 2018 San Diego, California. (poster presentation)
- **Vision gains with ranibizumab in eyes with diabetic macular edema and retinal nonperfusion at the macula.** R. Reddy, June S, Ghanekar A, Quezada Ruiz C. Podium Presentation San Francisco, CA. ASRS 2016
- **Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities. Poster presentation (#3074) at 54th American Society for Therapeutic Radiation Oncology K. Turaka, J. S. Bryan, H. M. Kwong Jr., S. De Souza, A. J. Gordon, M. C. Ziemianski, C. H. Sell, R. Reddy. (ASTRO) 2012 Annual Meeting, Boston, MA October 28-31, 2012.**
- **Vitreoretinal Lymphoma and Intravitreal Chemotherapy: Ocular and Systemic Outcomes.** Kiran Turaka, Alan J. Gordon, J. Shepard Bryan, Henry M. Kwong Jr., Stephen De Souza, Matthew C. Ziemianski, Clive H. Sell, Rahul Reddy. Poster presentation at the Pan Pacific Lymphoma Conference (PPLC), July 17-20, 2012, Island of Maui, Hawaii. Received the Travel grant award for the poster presentation.
- **“Intravitreal ketorolac for chronic inflammation and retinal edema study. A phase 1 safety study.”** R Reddy, Kim SJ. ASRS 2010.
- **“Systemic Adverse events among infants with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab”**
R Reddy, Recchia FM (paper presentation ARVO 2010 www.arvo.org)
- **“A Histopathologic analysis of transconjunctival sutureless vitrectomy wounds.”**
R Reddy, S S. Huang, L. Rao, P. Ferrone. ARVO 2009 www.arvo.org
- **“Morphologic analysis of cystoid macular edema in non-infectious uveitis treated with Flucinolone Acetonide intravitreal implant: 3 year results of a multi-center clinical trial”**
R Reddy. S.S Huang, AR Mercante ARVO 2007 www.arvo.org
- **“Met-analysis of ocular complications associated with Intravitreal Triamcinolone Acetonide.”**
R. Reddy, SS. Huang, Mohahmed Shaker Al Omran. ARVO 2006 www.arvo.org
- **“Extra-nodal marginal zone lymphoma in children.”**
R. Reddy, S. Dubovy, G. Byrne. ARVO 2004 www.arvo.org

Publications:

- **Efficacy of Ranibizumab in eyes with Diabetic macular edema and macular nonperfusion in RIDE and RISE.** R Reddy, Dante J. Pieramici, Caroline R. Baumal, Shamika Gune, Avanti Ghanekar, Na Lu, Carlos Quezada Ruiz. (Conditionally accepted Ophthalmology)
- **Handbook of Nutrition, Diet, and the Eye-second edition.** (Chapter in process)
- **Combination of Intravitreal bevacizumab and dexamethasone for diabetic macular edema.** (in process of submission)
- **The Evolution of Vitreoretinal Surgery Platforms.** Comaratta M, Hariprasad S, Reddy RK. *Ophthalmic Surgery, Lasers and Imaging Retina.* July 2017. Vol 48 (7):532-548.
- **Iluvien protocol (in progress)**
- **Serous Neurosensory Retinal detachment Associated with Atypical Cogans Syndrome:** Singer J, Reddy R. *Retin Cases Brief Rep.* 2015 Fall;9(4):315-9.
- **Treatment of Vitamin A Deficiency-Retinopathy with Sublingual Vitamin A Palmitate: A Case Report and Review of the Literature.** Singer JR, Bakall B, Gordon GM, Reddy R. *Documenta Ophthalmologica* 132(2):137-145.
- **Corticosteroid implants for chronic non-infectious uveitis.** Brady CJ, Villanti AC, Law HA, Rahimy E, Reddy R, Sieving PC, Garg SJ, Tang J. *Cochrane Database Syst Rev.* 2016 Feb 12;2:CD011469(Epub ahead of print) Review.
- **Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) study: findings at 3 months** Reddy, R., Lalezary M., Kim, S.J., Kammer, J., Kuchtey, E., Cherney, E., Recchia, F., Joos, K., Agarwal, A., Law, J.C. 2013 Sep 2 *Clin Ophthalmol.* 2013;7:1761-9. doi: 10.2147/OPHTH.S49375. Epub 2013 Sep 2.

- **Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study: Twelve-Month Findings.** Lalezary M, Shah RJ, Reddy RK, Kammer JA, Kuchtey RW, Joos KM, Cherney EF, Recchia FM, Kim SJ. *Ophthalmology*. 2014 June 3 (ahead of print).
- **“Clinical and image-guided chorioretinal findings in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency.”** Turaka, K., Bryan, J. S., Gordon, A. J., Kwong, H. M., Reddy, R., Tsipursky, M., Sell, C. H.; *J Pediatr Endocrinol Metab*. 2012 Aug 11.
- **“Laser pointer induced macular damage: case report and mini review.”** Turaka, K., Bryan, J. S., Gordon, A. J., Reddy, R., Kwong, H. M., Sell, C. H.; *Int Ophthalmol*. 2012 Apr 03
- **“Bilateral ischemic maculopathy in acquired immune deficiency syndrome.”** Turaka K, Golshani A, Khaw WY, Bryan JS., Reddy R. *J Ophthalmic Inflamm Infect*. 2013 Jan 15;3(1):15.
- **“Timeline for the management of suprachoroidal hemorrhage.”** Reddy R, Agarwal A. *Highlights of Ophthalmology; issue #3 2010*
- **“Intraocular T cell lymphoma in the setting of mycosis fungoides and response to intravitreal methotrexate. *Ocular Immunology and inflammation.*”** Reddy R., K. Kim SJ. *Ocul Immunol Inflamm*. 2011 Aug;19(4):234-6.
- **Critical Appraisal of Ophthalmic Ketorolac in Treatment of Pain and Inflammation after Cataract Surgery.** Reddy R, Kim SJ. *Clin Ophthalmol*. 2011;5:751-8. doi: 10.2147/OPTH.S7633. Epub 2011 Jun 3.
- **“Lymphoproliferative Disorders of the Ocular Adnexae. The Ophthalmic Hyperguide”** Reddy RK, Dubovy SR, Johnson TE. www.opthalmichyperguide.com. Online Chapter. 2004
- **“Deregulation of glucose transporter 1 and glycolytic gene expression by c”** Osthus RL, Reddy RK, Shim H, Li Q, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang C. 2000 *Myc. J. Biol. Chem.* July, 275(29):21797-21800

Research Experience:

Associated Retina Consultants, Ltd., Phoenix, AZ

Aug 2011 – Present

Principal Investigator

- **EYEGATE Pharma Protocol EGP-437-004:** A prospective, multi-center, randomized, double-masked, positive-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of Iontophoretic Dexamethasone phosphate ophthalmic solution compared to Prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis
- **XOMA Protocol X052130:** A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis
- **XOMA Protocol X052131:** A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-Uveitis Currently Controlled with Systemic Treatment

Sub-Investigator

- **Alcon Research, Ltd. Protocol C-10-083:** Safety and Efficacy of ESBA1008 versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration
- **Alcon Research, Ltd. Protocol C-12-006:** A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1108 versus EYLEA® in Subjects with Exudative Age-Related Macular Degeneration
- **Banner Alzheimer’s Institute Eli Lilly Protocol I40-MC-BACC(b):** Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease
- **Banner Alzheimer’s Institute Cognoptix, Inc. Protocol NEU03:** Feasibility Study: Safety and Efficacy Assessment of SAPHIRE II System to Aid in the Diagnosis of Probable Alzheimer’s disease in twenty normal subjects and twenty patients with probable Alzheimer’s disease
- **Banner Alzheimer’s Institute Merck Sharp & Dohme Corp. Protocol P07738:** A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease
- **FOVEA Pharmaceutical SA Protocol FOV2304:** A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1 % and 2 %) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy
- **Genentech, Inc. Protocol FVF4168g (RIDE):** A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (*CLOSED*)

- **Genentech, Inc. Protocol FVF 4579g (HARBOR):** A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an An-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
- **Genentech, Inc. Protocol FVF4967g (SHORE):** A Multicenter Randomized Study for Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion
- **GlaxoSmithKline Protocol MD7110852:** A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
- **GlaxoSmithKline Protocol BAM114341:** A Phase 2, Multi-centre, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
- **LPATH, Inc. Protocol LT1009-Oph-003:** A Phase 2a, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP™ (Sonepcizumab [LT1009]) as Either Monotherapy or Adjunctive Therapy to Lucentis® or Avastin® Versus Lucentis® or Avastin® Alone for the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- **Novartis Institutes for BioMedical Research Protocol CLFG316A2203:** A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration
- **Pfizer Protocol B1181003:** A Phase 2 Multi-Center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
- **Southwest Center for HIV: EMD Serono Inc. Protocol EMR200147-500:** A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg once daily, SC, increases the risk of development or progression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes
- **Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0819:** A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (*CLOSED*)
- **Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0910:** An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration
- **Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-1009:** A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema
- **Regeneron Pharmaceuticals, Inc. Protocol VGFTe-AMD-1124:** An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration
- **A prospective analysis of nerve fiber layer and macular changes after pars plana vitrectomy.**
 - Investigating the anatomic and functional changes of the macula and optic nerve after pars plana vitrectomy in order to establish their incidence, characterize the quality and extent of these changes, and determine pre-disposing risk factors.

The Vanderbilt Eye Institute, Nashville, TN
Vitreo-retinal fellow

July 2009 – July 2011

- Teaching residents
- Clinical Instructor Vanderbilt University

Bascom Palmer Eye Institute, Miami, FL
Ocular pathology fellow

Jul 2003 – Jul 2004

- Teaching residents ocular pathology
- Involved in the clinic- pathologic correlation of tissue specimens
- Involved in the management of an ocular pathology laboratory
- Investigating orbital lymphoma and genetic characterization of variants

Johns Hopkins Hospital, Dept. of Hematology, Baltimore, MD
Research assistant

Jul 1998 – Jun 1999

- Studied lipid metabolism and its putative role in cancer
- Investigated the cellular pathways involved in cancer metastasis using nuclear lipid receptors
- Isolated genes, which were up-regulated in cells transformed with c-Myc, in a hypoxic environment

National Cancer Institute, IRTA Fellowship Award, Bethesda, MD

Jun 1996 – Jul 1997

Research assistant

- Introduced tumors into a *Drosophila* background and breded different lines to find those which are resistant to the tumor.
- Isolated the tumor suppressing gene products with micro-dissection and invasion assays
- Searched the human genome with *Drosophila* gene probes to find putative tumor suppressor genes

University of Cincinnati, Microbiology Department, Cincinnati, OH

Jun 1995 – Jun 1996

Research assistant

- Investigated the protozoan *Leishmania Donavani* to elucidate survival mechanisms
- Characterized a putative ATPase gene which enabled the organism to survive in the acidic environment of the human macrophage.